{"denoms":[{"counts":[{"groupId":"BG000","value":"167"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"168"},{"groupId":"BG003","value":"168"},{"groupId":"BG004","value":"670"}],"units":"Participants"}],"groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"BG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"BG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"BG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"BG003","title":"Dasatinib 70 mg BID"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"130"},{"groupId":"BG003","value":"125"},{"groupId":"BG004","value":"504"}]}],"title":"Less than, equal to (<=) 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"166"}]}],"title":"Greater than (>) 65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"83"},{"groupId":"BG003","value":"91"},{"groupId":"BG004","value":"354"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"85"},{"groupId":"BG003","value":"77"},{"groupId":"BG004","value":"316"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"88"},{"groupId":"BG003","value":"81"},{"groupId":"BG004","value":"322"}]}],"title":"Primary Resistance to Imatinib"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"175"}]}],"title":"Acquired Resistance to Imatinib"},{"categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"42"},{"groupId":"BG004","value":"173"}]}],"title":"Intolerant to Imatinib"}],"description":"Primary Resistance: no decrease in white blood cell (WBC) count after ≥ 4 weeks imatinib or not achieved a complete hematologic response (CHR) after 3 months, a major cytogenetic response (MCyR) after 6 months, or a complete cytogenetic response (CCyR) after 12 months. Acquired resistance: achieved MCyR and no longer met the criteria for MCyR. Intolerance: Grade ≥ 3 toxicity considered at least possibly related to imatinib at a dose of ≤ 400 mg/day which led to discontinuation of therapy; tolerated the dose of 400 mg but did not achieve a CCyR and subsequently did not tolerate doses ≥ 600 mg.","paramType":"NUMBER","title":"Imatinib Status","unitOfMeasure":"participants"}],"populationDescription":"All participants randomized to a treatment arm are summarized."}